Erdheim–Chester disease with cardiac involvement. Case report
- 作者: Latyshev V.1, Mershina E.2, Kostina I.1, Sinitsyn V.2, Lukina E.1
-
隶属关系:
- National Research Center for Hematology
- Lomonosov Moscow State University
- 期: 卷 94, 编号 7 (2022)
- 页面: 897-902
- 栏目: Clinical notes
- URL: https://journals.rcsi.science/0040-3660/article/view/109745
- DOI: https://doi.org/10.26442/00403660.2022.07.201737
- ID: 109745
如何引用文章
全文:
详细
Erdheim–Chester disease (ECD) is a rare non-Langerhans histiocytosis with multisystem inflammatory infiltrates consistent of monocytes/macrophages, reactive microenvironment and fibrotic fields. Cardiovascular involvement is one of the most frequent manifestations of ECD that can lead to life threating complications. In this article we are reporting a clinical case of ECD with cardiac involvement in a young patient.
作者简介
Vitalii Latyshev
National Research Center for Hematology
编辑信件的主要联系方式.
Email: LatyshevVD@gmail.com
ORCID iD: 0000-0003-0643-8807
врач-гематолог отд-ния орфанных заболеваний
俄罗斯联邦, MoscowElena Mershina
Lomonosov Moscow State University
Email: LatyshevVD@gmail.com
ORCID iD: 0000-0002-1266-4926
канд. мед. наук, доц. каф. лучевой диагностики и лучевой терапии, зав. отд-нием рентгенодиагностики с кабинетами МРТ и КТ
俄罗斯联邦, MoscowIrina Kostina
National Research Center for Hematology
Email: LatyshevVD@gmail.com
ORCID iD: 0000-0003-4683-4118
канд. мед. наук, врач-рентгенолог, зав. отд-нием рентгенологии и компьютерной томографии
俄罗斯联邦, MoscowValentin Sinitsyn
Lomonosov Moscow State University
Email: LatyshevVD@gmail.com
ORCID iD: 0000-0002-5649-2193
д-р мед. наук, проф., зав. каф. лучевой диагностики и лучевой терапии фак-та фундаментальной медицины, рук. отд. лучевой диагностики университетской клиники
俄罗斯联邦, MoscowElena Lukina
National Research Center for Hematology
Email: LatyshevVD@gmail.com
ORCID iD: 0000-0002-8774-850X
д-р мед. наук, проф., зав. отд-нием орфанных заболеваний
俄罗斯联邦, Moscow参考
- Cohen-Aubart F, Emile J-F, Carrat F, et al. Phenotypes and survival in Erdheim-Chester disease: Results from a 165-patient cohort. Am J Hematol. 2018;93:E114-7. doi: 10.1002/ajh.25055
- Pegoraro F, Papo M, Maniscalco V, et al. Erdheim–Chester disease: a rapidly evolving disease model. Leukemia. 2020;34:2840-57. doi: 10.1038/s41375-020-0944-4
- Haroche J, Cohen-Aubart F, Amoura Z. Erdheim-Chester disease. Blood. 2020;135:1311-8. doi: 10.1182/blood.2019002766
- Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012;120:2700-3. doi: 10.1182/blood-2012-05-430140
- Emile J-F, Diamond EL, Hélias-Rodzewicz Z, et al. Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood. 2014;124:3016-9. doi: 10.1182/blood-2014-04-570937
- Diamond EL, Durham BH, Haroche J, et al. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discov. 2016;6:154-65. doi: 10.1158/2159-8290.CD-15-0913
- Goyal G, Heaney ML, Collin M, et al. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood. 2020;135:1929-45. doi: 10.1182/blood.2019003507
- Cives M, Simone V, Rizzo FM, et al. Erdheim–Chester disease: A systematic review. Crit Rev Oncol Hematol. 2015;95:1-11. doi: 10.1016/j.critrevonc.2015.02.004
- Estrada-Veras JI, O’Brien KJ, Boyd LC, et al. The clinical spectrum of Erdheim-Chester disease: an observational cohort study. Blood Adv. 2017;1:357-66. doi: 10.1182/bloodadvances.2016001784
- Arnaud L, Hervier B, Néel A, et al. CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood. 2011;117:2778-82. doi: 10.1182/blood-2010-06-294108
- Goyal G, Shah MV, Call TG, et al. Efficacy of biological agents in the treatment of Erdheim–Chester disease. Br J Haematol. 2018;183:520-4. doi: 10.1111/bjh.14997
- Arnaud L, Gorochov G, Charlotte F, et al. Systemic perturbation of cytokine and chemokine networks in Erdheim–Chester disease: a single-center series of 37 patients. Blood. 2011;117:2783-90. doi: 10.1182/blood-2010-10-313510
- Diamond EL, Subbiah V, Lockhart AC, et al. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis. JAMA Oncol. 2018;4:384. doi: 10.1001/jamaoncol.2017.5029
- Diamond EL, Durham BH, Ulaner GA, et al. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019;567:521-4. doi: 10.1038/s41586-019-1012-y
- Haroche J, Amoura Z, Dion E, et al. Cardiovascular Involvement, an Overlooked Feature of Erdheim-Chester Disease. Medicine (Baltimore). 2004;83:371-92. doi: 10.1097/01.md.0000145368.17934.91
- Haroche J, Cluzel P, Toledano D, et al. Cardiac Involvement in Erdheim-Chester Disease. Circulation. 2009;119. doi: 10.1161/CIRCULATIONAHA.108.825075
- Chester W. Über Lipoidgranulomatose. Virchows Arch Pathol Anat Physiol Klin Med. 1930;279:561-602. doi: 10.1007/BF01942684
- Gianfreda D, Palumbo AA, Rossi E, et al. Cardiac involvement in Erdheim-Chester disease: an MRI study. Blood. 2016;128:2468-71. doi: 10.1182/blood-2016-07-724815
- Ghotra AS, Thompson K, Lopez-Mattei J, et al. Cardiovascular manifestations of Erdheim–Chester disease. Echocardiography. 2019;36:229-36. doi: 10.1111/echo.14231
- Costa IBS da S, Abdo ANR, Bittar CS, et al. Cardiovascular Manifestations of Erdheim-Chester’s Disease: A Case Series. Arq Bras Cardiol. 2018. doi: 10.5935/abc.20180218
- Villatoro-Villar M, Bold MS, Warrington KJ, et al. Arterial involvement in Erdheim–Chester disease. Medicine (Baltimore). 2018;97:e13452. doi: 10.1097/MD.0000000000013452
- Das JP, Xie L, Riedl CC, et al. Cardiothoracic manifestations of Erdheim-Chester disease. Br J Radiol. 2019;92:20190473. doi: 10.1259/bjr.20190473
- Saunders IM, Goodman AM, Kurzrock R. Real-World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim-Chester Disease. Oncologist. 2020;25. doi: 10.1634/theoncologist.2019-0606